| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Other Events
On November 3, 2026, Nurix Therapeutics, Inc. (the “Company”) announced that collaboration partner Sanofi S.A. (“Sanofi”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an ... |
| 13 Oct 2026 |
8-K: Results of Operations and Financial Condition
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL |
| 09 Jul 2026 |
8-K: Results of Operations and Financial Condition
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment |
| 11 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy |
| 08 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Unlocking the Full Potential of Bexobrutideg A Global Collaboration Between Nurix and Roche June 8, 2026 Exhibit 99.2 |
| 15 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 15, 2026, Nurix Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders exclusively online via live webcast (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals... |
| 08 Apr 2026 |
8-K: Results of Operations and Financial Condition
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) |
| 06 Mar 2026 |
8-K: Other Events
We deliver this opinion with respect to certain matters in connection with the offering by Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), of the Company’s common stock, $0.001 par value per share (the “Common Stock”), ... |
| 28 Jan 2026 |
8-K: Results of Operations and Financial Condition
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases |
| 09 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from ASH 2025 American Society of Hematology December 8, 2025 Exhibit 99.3 |
| 10 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise |
| 22 Oct 2025 |
8-K: Other Events
Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”)... |
| 22 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Bexobrutideg Investor Update Investor Presentation October 2025 |
| 09 Oct 2025 |
8-K: Results of Operations and Financial Condition
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure
Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025 |
| 22 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 19, 2025, Lori A. Kunkel, M.D., advised the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) that she would resign as a Class III director of the Board, and as chair of the Clinical and Commercializa... |
| 09 Jul 2025 |
8-K: Results of Operations and Financial Condition
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM) |
| 12 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from EHA European Hematological Association Investor Event June 12, 2025 |
| 19 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 19, 2025, Nurix Therapeutics, Inc. (the “Company”) held its virtual 2025 Annual Meeting of Stockholders exclusively online via live webcast (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three p... |
Loading...